First-line therapy of osimertinib with chemotherapy in Chinese patients with EGFR mutation–positive non–small cell lung cancer: protocol for a multicenter, prospective, observational study

Epidermal growth factor receptor (EGFR) gene mutations are the most common oncogenic-genomic driver in non-small cell lung cancer (NSCLC), with highest prevalence (30%-50%) in Asian patients. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) is the preferred first-line (1L) t...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Bo Zhang, Fangling Ning, Xiaomei Liu, Na Li, Pingfei Wang, Wenxiu Yao, Baohui Han, Qiming Wang, Hua Zhong
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2025-09-01
סדרה:	Frontiers in Oncology
נושאים:	non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitor osimertinib real-world study
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1625714/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!